NCT07169331进行中（未招募）4 期
A Phase 4, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Patients With Treatment-Naive Waldenström Macroglobulinemia
BeiGene7 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2025年10月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
- 试验地点
- 7
- 主要终点
- Percentage of Participants Achieving a Complete Response (CR) or Very Good Partial Response (VGPR) as Assessed by the Investigator
研究概览
简要总结
The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical and definitive histologic diagnosis of WM. Participant must be treatment-naive.
- •Participant must meet at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenström's macroglobulinemia (IWWM).
- •Participant must have measurable disease, as defined by serum immunoglobulin M (IgM) level > 0.5 g/dL.
- •Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to
- •Participants must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study treatment:
- •Participants must not have required blood transfusion or growth factor support ≤ 7 days before sample collection at screening for the following:
- •Absolute neutrophil count (ANC) ≥ 0.75 x 10^9/L.
- •Platelets ≥ 50 x 10^9/L.
- •Creatinine clearance of ≥ 30 ml/min as estimated by the Cockcroft-Gault formula.
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN).
- •Serum total bilirubin ≤ 2 x ULN (total bilirubin must be < 3 x ULN for participants with Gilbert syndrome).
- •Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for at least 1 month after the last dose of zanubrutinib. They must also have a negative urine or serum pregnancy test result ≤ 7 days before the first dose of study treatment.
排除标准
- •Evidence of disease transformation at the time of study entry.
- •Central nervous system (CNS) involvement by WM. Patients with a history of CNS involvement must undergo magnetic resonance imaging (MRI) and cerebrospinal fluid cytology studies to document no evidence of CNS disease prior to study entry.
- •Evidence of disease transformation at the time of study entry.
- •Participants with any of the following cardiovascular risk factors:
- •Active cardiac ischemia (eg, cardiac chest pain) ≤ 28 days before first dose of study drug.
- •Any history of acute myocardial infarction ≤ 6 months before the first dose of study drug.
- •Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 7)≤ 6 months before the first dose of study drug.
- •Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before the first dose of study drug.
- •Active, clinically significant second-degree atrioventricular block Mobitz II, or third degree atrioventricular block.
- •Any history of cerebrovascular accident ≤ 6 months before the first dose of study drug.
- •Uncontrolled hypertension that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug.
- •Any episode of syncope or seizure ≤ 28 days before first dose of study drug.
- •At the time of study entry, participants taking warfarin or other vitamin K antagonists.
- •Participants requiring ongoing therapy with strong or moderate cytochrome CYP3A inducers
- •Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy, targeted therapy, or radiation therapy within 4 weeks, or antibody-based therapy within 4 weeks before the start of study drug.
- •Major surgical procedure within 4 weeks before the start of study treatment (bone marrow aspirate and biopsy procedures are not considered major surgical procedures).
- •Note: Other protocol defined criteria may apply
研究组 & 干预措施
Zanubrutinib
Experimental
Participants will receive 160 mg zanubrutinib orally twice a day until progressive disease, unacceptable toxicity or death, withdrawal of consent, loss to follow-up, or study termination by the sponsor for any reason.
干预措施: Zanubrutinib (Drug)
结局指标
主要结局
Percentage of Participants Achieving a Complete Response (CR) or Very Good Partial Response (VGPR) as Assessed by the Investigator
时间窗: Up to approximately 33 Months
The percentage of participants who achieve either a complete response or very good partial response (VGPR) as determined by the investigator using an adaptation of the response criteria updated at the Sixth International Workshop on Waldenström's macroglobulinemia (IWWM).
次要结局
- Major Response Rate (MRR) as Assessed by the Investigator(Up to approximately 33 Months)
- Duration of Major Response (DOMR) as Assessed by the Investigator(Up to approximately 33 Months)
- Progression-free Survival (PFS) as Assessed by the Investigator(Up to approximately 33 Months)
- Number of Participant with Adverse Events (AEs) and Serious Adverse Events (SAEs)(From first dose of study drug until 30 days after the last dose, up to approximately 33 months)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Refractory Mantle Cell LymphomaRelapsed Mantle Cell LymphomaNCT03206970BeiGene86
招募中
2 期
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular LymphomaFollicular LymphomaNewly DiagnosedNCT06553352The First Affiliated Hospital of Xiamen University39
尚未招募
2 期
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Follicular LymphomaNCT06549335Ruijin Hospital66
已完成
1 期
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver FunctionHepatic Insufficiency & Healthy SubjectsNCT03465059BeiGene29
已完成
2 期
Zanubrutinib in Participants With Active Proliferative Lupus NephritisLupus NephritisNCT04643470BeiGene177